NO952981L - Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin - Google Patents

Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin

Info

Publication number
NO952981L
NO952981L NO952981A NO952981A NO952981L NO 952981 L NO952981 L NO 952981L NO 952981 A NO952981 A NO 952981A NO 952981 A NO952981 A NO 952981A NO 952981 L NO952981 L NO 952981L
Authority
NO
Norway
Prior art keywords
cyclodextrin
embedding
acid
multicomponent
resolution
Prior art date
Application number
NO952981A
Other languages
English (en)
Norwegian (no)
Other versions
NO952981D0 (no
Inventor
Paolo Chiesi
Paolo Ventura
Massimo Pasini
Joesef Szejtli
Maria Vikmon
Enrico Redenti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO952981D0 publication Critical patent/NO952981D0/no
Publication of NO952981L publication Critical patent/NO952981L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO952981A 1993-01-29 1995-07-27 Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin NO952981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI930141A IT1263831B (it) 1993-01-29 1993-01-29 Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
PCT/EP1994/000205 WO1994016733A1 (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin

Publications (2)

Publication Number Publication Date
NO952981D0 NO952981D0 (no) 1995-07-27
NO952981L true NO952981L (no) 1995-07-27

Family

ID=11364792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952981A NO952981L (no) 1993-01-29 1995-07-27 Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin

Country Status (18)

Country Link
US (1) US5855916A (pt)
EP (1) EP0681481B1 (pt)
JP (1) JPH08508711A (pt)
KR (1) KR960700074A (pt)
AT (1) ATE228013T1 (pt)
AU (1) AU691115B2 (pt)
BR (1) BR9406779A (pt)
CA (1) CA2154874A1 (pt)
CZ (1) CZ284606B6 (pt)
DE (1) DE69431747D1 (pt)
FI (1) FI953590A (pt)
HU (1) HU218796B (pt)
IL (1) IL108460A (pt)
IT (1) IT1263831B (pt)
NO (1) NO952981L (pt)
NZ (1) NZ261115A (pt)
WO (1) WO1994016733A1 (pt)
ZA (1) ZA94572B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
AUPM456894A0 (en) * 1994-03-18 1994-04-14 Glyzinc Pharmaceuticals Limited Treatment for gastric disorders
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127956A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
PT893121E (pt) * 1997-06-27 2002-06-28 Akzo Nobel Nv Solucao medicinal liquida oral
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
JP2000080123A (ja) * 1998-09-03 2000-03-21 Toagosei Co Ltd シアノアクリレート用硬化促進剤
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
FI982733A (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US6740639B1 (en) * 2000-03-29 2004-05-25 Council Of Scientific & Industrial Research Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US20060199778A1 (en) * 2001-09-19 2006-09-07 Rutledge Ellis-Behnke Methods and products related to non-viral transfection
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
EP1515703A1 (en) 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
CN1515260B (zh) * 2003-06-26 2010-05-05 沈阳药科大学 含hpcd的桂利嗪粉针剂和其固体制剂及其制备方法
WO2005047334A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Igg fc fragment for a drug carrier and method for the preparation thereof
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1570862A1 (en) * 2004-02-25 2005-09-07 JPM - The Jordanian Pharmaceutical Manufacturing Co. Ltd. Highly soluble binary cyclodextrin inclusion complexes
EP1718640A4 (en) * 2004-02-26 2008-01-09 Transform Pharmaceuticals Inc NEW CRYSTALLINE FORMS OF CONAZOLES AND METHOD FOR THEIR PREPARATION AND APPLICATION
KR100663079B1 (ko) * 2004-06-24 2007-01-02 주식회사 씨티씨바이오 이트라코나졸 함유 고체분산체의 제조방법
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
CA2729819C (en) 2008-07-03 2014-08-26 University Of Virginia Patent Foundation Unit dosage of apadenoson
ES2464729T3 (es) 2008-08-21 2014-06-03 The Johns Hopkins University Procedimientos y composiciones para la administración de 3-halopiruvato y compuestos relacionados para el tratamiento del cáncer
CN102458114A (zh) 2009-05-29 2012-05-16 锡德克斯药物公司 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
JP5803150B2 (ja) * 2011-03-02 2015-11-04 三菱瓦斯化学株式会社 ピロロキノリンキノンーシクロデキストリン包接体
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
WO2015108933A1 (en) * 2014-01-14 2015-07-23 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
WO2016072985A1 (en) 2014-11-05 2016-05-12 Halliburton Energy Services, Inc. Delayed acid breaker systems for filtercakes
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
CN106539752B (zh) * 2015-09-18 2019-10-29 成都康弘药业集团股份有限公司 一种含有阿立哌唑的口服溶液及其制备方法
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP4149427A1 (en) 2020-06-11 2023-03-22 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent
KR102356618B1 (ko) * 2021-11-17 2022-02-08 명지대학교 산학협력단 신규 포접복합체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS60185772A (ja) * 1984-03-05 1985-09-21 Mitsui Pharmaceut Inc 安定なカルモフ−ル−β−シクロデキストリンの包接化合物
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
JP2571199B2 (ja) * 1987-11-25 1997-01-16 塩水港精糖株式会社 溶解性の高いサイクロデキストリンの製造方法
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids

Also Published As

Publication number Publication date
DE69431747D1 (de) 2003-01-02
ITMI930141A0 (it) 1993-01-29
IT1263831B (it) 1996-09-04
ITMI930141A1 (it) 1994-07-30
NZ261115A (en) 1996-11-26
NO952981D0 (no) 1995-07-27
CZ194395A3 (en) 1996-01-17
FI953590A0 (fi) 1995-07-27
EP0681481A1 (en) 1995-11-15
CA2154874A1 (en) 1994-08-04
FI953590A (fi) 1995-09-14
EP0681481B1 (en) 2002-11-20
HU218796B (hu) 2000-12-28
JPH08508711A (ja) 1996-09-17
HU9502251D0 (en) 1995-09-28
US5855916A (en) 1999-01-05
AU691115B2 (en) 1998-05-07
IL108460A0 (en) 1994-04-12
IL108460A (en) 1999-01-26
CZ284606B6 (cs) 1999-01-13
AU5971094A (en) 1994-08-15
WO1994016733A1 (en) 1994-08-04
HUT72500A (en) 1996-05-28
KR960700074A (ko) 1996-01-19
BR9406779A (pt) 1996-02-06
ZA94572B (en) 1994-09-13
ATE228013T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
NO952981L (no) Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin
MY109880A (en) Substituted biphenylpyridones
DE68901986D1 (de) Turbomolekularpumpe und deren betriebsverfahren.
DE68924026D1 (de) Biosensor und dessen herstellung.
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
NO903898D0 (no) Fremgangsmaate for igjenplugging av en sone i en broenn.
ATE407362T1 (de) Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen
ATE67196T1 (de) Aminosaeureabkoemmlinge.
NO933966L (no) Stoff for senkning av hoeyt kolesterolnivaa i serum og fremgangsmaate for fremstilling av stoffet
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
ATE261972T1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
DE68912762D1 (de) Phasenkonjugiertes verstärkersystem und verfahren, mit vier durchfgängen.
NO892460D0 (no) Fremgangsmaate for reduksjon av nitrogenoxyder i et avloep.
DE68919172D1 (de) MOSFET und dessen Herstellungsverfahren.
NO885029D0 (no) FremgangsmŸte og anordning for presisjons-anbringelse av gjenstander pŸ faste konstruksjoner pŸ dypt vann.
NO891122D0 (no) Platinakoordinasjonsforbindelser og anvendelse av forbindelsene i kjemoterapi.
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
ES2056808T3 (es) Derivados de antraciclina activos citostaticamente.
ZA926969B (en) New beta-carboline derivatives, their production and use in pharmaceutical agents.
DE69010387D1 (de) Metastabile Metallkolloide und deren Herstellung.
FR2713444B1 (fr) Composition liquide désinfectante et ses utilisations.
DK0652635T3 (da) Differensforstærkningstrin til anvendelse i bipolære ECL-standardprocesser
DE3884010D1 (de) Dünnfilmtransistoren, Anzeigeanordnungen mit solchen Transistoren und Verfahren zu deren Herstellung.
FI941912A (fi) 3-kinolyylillä substituoidut dihydropyridiinit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application